Breaking News

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors

SEATTLE--(BUSINESS WIRE)-- #BLZ100--Blaze Bioscience Completed Enrollment on Pivotal Phase 2/3 Trial of tozuleristide and Canvas Imaging System in Pediatric Central Nervous System Tumors
http://dlvr.it/Sc6pX5